# Antiemetic Management â€“ Clinical Call Protocol

**Guidelines Referenced:**  
American Society of Clinical Oncology (ASCO) Antiemetic Guidelines 2020, National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines 2023, American Gastroenterological Association Clinical Practice Guidelines for Nausea and Vomiting 2021

**Official Sources:**  
https://ascopubs.org/doi/10.1200/JCO.20.01296  
https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf  
https://www.gastrojournal.org/article/S0016-5085(21)00487-1/fulltext

## CARD INTERFACE LAYOUT

### Card 0 â€“ Dynamic Action Card (Node Dependent)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ NAUSEA/VOMITING EVALUATION                                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“± CALLED BY: Oncology RN, Bed 18                          â”‚
â”‚ Patient: 54yo F, Day 2 post-chemotherapy (AC regimen)      â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     IMMEDIATE ASSESSMENT        â”‚                        â”‚
â”‚ â”‚ â˜‘ Vital signs obtained          â”‚ [BP 108/68, HR 96]     â”‚
â”‚ â”‚ â˜‘ Orthostatic vitals checked    â”‚ [Positive orthostatics]â”‚
â”‚ â”‚ â˜‘ Last antiemetic dose noted    â”‚ [Ondansetron 2h ago]   â”‚
â”‚ â”‚ â˜‘ Vomitus characteristics       â”‚ [Bilious, no blood]    â”‚
â”‚ â”‚ â˜ IV access verified           â”‚ [18G left AC patent]   â”‚
â”‚ â”‚ â˜ Hydration status assessed    â”‚ [Mild dehydration]     â”‚
â”‚ â”‚ â˜ Breakthrough protocol        â”‚ [Initiate per CINV]    â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ Current regimen: Ondansetron 8mgâ”‚                        â”‚
â”‚ â”‚ IV q8h (inadequate control)     â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ VITALS: BP 108/68, HR 96, RR 18, T 37.1Â°C                 â”‚
â”‚ Orthostatics: â†“ 16 mmHg SBP, â†‘ 24 bpm HR                  â”‚
â”‚                                                           â”‚
â”‚ PRESENTATION:                                              â”‚
â”‚ â€¢ 6 episodes vomiting since midnight                       â”‚
â”‚ â€¢ Unable to tolerate PO fluids                            â”‚
â”‚ â€¢ Bilious vomitus, no hematemesis                          â”‚
â”‚ â€¢ Last bowel movement yesterday                            â”‚
â”‚                                                           â”‚
â”‚ ğŸš¨ CINV BREAKTHROUGH - High emetogenic chemotherapy        â”‚
â”‚ Requires multimodal antiemetic approach with hydration     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Example - CINV Breakthrough Management Node:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ CINV BREAKTHROUGH PROTOCOL ACTIVATED                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CHEMOTHERAPY REGIMEN: AC (Adriamycin + Cyclophosphamide)    â”‚
â”‚ Day 2 post-infusion, high emetogenic potential             â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     BREAKTHROUGH STRATEGY       â”‚                        â”‚
â”‚ â”‚ â˜‘ Metoclopramide 10mg IV STAT   â”‚ [Given 14:30]          â”‚
â”‚ â”‚ â˜‘ Dexamethasone 8mg IV x1       â”‚ [Anti-inflammatory]    â”‚
â”‚ â”‚ â˜‘ Lorazepam 0.5mg IV q6h PRN    â”‚ [Anticipatory anxiety] â”‚
â”‚ â”‚ â˜ NS bolus 500mL                â”‚ [For dehydration]      â”‚
â”‚ â”‚ â˜ If refractory (>30min):       â”‚                        â”‚
â”‚ â”‚   Haloperidol 0.5-1mg IV        â”‚ [Different mechanism]  â”‚
â”‚ â”‚   Consider olanzapine 10mg       â”‚ [Broad spectrum]       â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ Avoid ondansetron x 4 hours     â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ ADDITIONAL SUPPORTIVE CARE:                                â”‚
â”‚ â€¢ IV fluids: NS 125mL/hr continuous                        â”‚
â”‚ â€¢ Electrolyte panel in AM (hypokalemia risk)               â”‚
â”‚ â€¢ Strict input/output monitoring                           â”‚
â”‚ â€¢ Anti-acid therapy: Famotidine 20mg IV BID                â”‚
â”‚                                                           â”‚
â”‚ REASSESSMENT PLAN:                                         â”‚
â”‚ â€¢ Evaluate response in 30 minutes                          â”‚
â”‚ â€¢ Next scheduled dose options in 4-6 hours                 â”‚
â”‚ â€¢ Consider admission if no improvement                      â”‚
â”‚                                                           â”‚
â”‚ PREVENTION FOR NEXT CYCLE:                                 â”‚
â”‚ â€¢ Add NK-1 antagonist (aprepitant)                         â”‚
â”‚ â€¢ Increase steroid dose pre-treatment                      â”‚
â”‚ â€¢ Consider prophylactic olanzapine                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Example - Cannabinoid Hyperemesis Syndrome Node:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ CANNABINOID HYPEREMESIS SYNDROME SUSPECTED                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ CLINICAL PRESENTATION CONSISTENT:                           â”‚
â”‚ â€¢ Chronic daily cannabis use confirmed (5+ years)           â”‚
â”‚ â€¢ Cyclic vomiting episodes                                  â”‚
â”‚ â€¢ Compulsive hot shower behavior                            â”‚
â”‚ â€¢ Resolution with cannabis cessation previously             â”‚
â”‚                                                           â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                        â”‚
â”‚ â”‚     SPECIFIC CHS TREATMENT      â”‚                        â”‚
â”‚ â”‚ â˜‘ Haloperidol 5mg IV/IM        â”‚ [Most effective agent] â”‚
â”‚ â”‚ â˜‘ Capsaicin cream 0.1%         â”‚ [Apply to abdomen]     â”‚
â”‚ â”‚ â˜‘ Hot shower privileges        â”‚ [Patient preference]   â”‚
â”‚ â”‚ â˜ Lorazepam 1mg IV PRN         â”‚ [Anxiety component]    â”‚
â”‚ â”‚                                â”‚                        â”‚
â”‚ â”‚ AVOID (ineffective in CHS):    â”‚                        â”‚
â”‚ â”‚ â€¢ Opioids (worsen symptoms)    â”‚                        â”‚
â”‚ â”‚ â€¢ Standard 5-HT3 antagonists   â”‚                        â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                                                           â”‚
â”‚ SUPPORTIVE MEASURES:                                       â”‚
â”‚ â€¢ Aggressive IV fluid resuscitation (often severely dehydrated)â”‚
â”‚ â€¢ Electrolyte monitoring and repletion                     â”‚
â”‚ â€¢ Thiamine 100mg IV (nutritional deficiency risk)          â”‚
â”‚ â€¢ Cannabis cessation counseling                            â”‚
â”‚                                                           â”‚
â”‚ DISPOSITION:                                               â”‚
â”‚ â€¢ Admission likely required for symptom control            â”‚
â”‚ â€¢ Psychiatry/addiction medicine consultation               â”‚
â”‚ â€¢ Discharge planning with cannabis cessation resources     â”‚
â”‚                                                           â”‚
â”‚ PATIENT EDUCATION:                                         â”‚
â”‚ â€¢ CHS diagnosis explanation                                â”‚
â”‚ â€¢ Cannabis cessation as definitive treatment              â”‚
â”‚ â€¢ Symptom recurrence with continued use                   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 1 â€“ Static Assessment/Causes & Risk Factors

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ NAUSEA/VOMITING CAUSES & RISK FACTORS                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ GASTROINTESTINAL CAUSES:                                   â”‚
â”‚ â€¢ Gastroparesis (diabetes, post-viral)                     â”‚
â”‚ â€¢ Small bowel obstruction/ileus                            â”‚
â”‚ â€¢ Pancreatitis, cholecystitis, hepatitis                   â”‚
â”‚ â€¢ GERD, peptic ulcer disease                               â”‚
â”‚                                                           â”‚
â”‚ MEDICATION-INDUCED (#1 cause):                             â”‚
â”‚ â€¢ Opioids (most common), antibiotics, digoxin             â”‚
â”‚ â€¢ Chemotherapy (high/moderate emetogenic)                  â”‚
â”‚ â€¢ Iron supplements, metformin, NSAIDs                      â”‚
â”‚                                                           â”‚
â”‚ METABOLIC/ENDOCRINE:                                       â”‚
â”‚ â€¢ Uremia, hypercalcemia, DKA, pregnancy                    â”‚
â”‚ â€¢ Adrenal insufficiency, thyroid disorders                â”‚
â”‚                                                           â”‚
â”‚ NEUROLOGIC/PSYCHIATRIC:                                    â”‚
â”‚ â€¢ Increased ICP, migraine, vestibular disorders            â”‚
â”‚ â€¢ Motion sickness, anxiety disorders                       â”‚
â”‚ â€¢ Cannabinoid hyperemesis syndrome                         â”‚
â”‚                                                           â”‚
â”‚ RED FLAG FEATURES:                                         â”‚
â”‚ â€¢ Projectile vomiting (increased ICP)                      â”‚
â”‚ â€¢ Hematemesis (upper GI bleeding)                          â”‚
â”‚ â€¢ Severe dehydration with hemodynamic compromise           â”‚
â”‚ â€¢ Altered mental status, focal neurologic signs            â”‚
â”‚ â€¢ Bilious vomiting with abdominal distension               â”‚
â”‚                                                           â”‚
â”‚ HIGH-RISK PATIENT GROUPS:                                  â”‚
â”‚ â€¢ Post-operative patients (anesthesia, opioids)            â”‚
â”‚ â€¢ Chemotherapy recipients (CINV)                           â”‚
â”‚ â€¢ Elderly (polypharmacy, dehydration risk)                â”‚
â”‚ â€¢ Pregnancy (hyperemesis gravidarum)                      â”‚
â”‚ â€¢ Chronic pain patients (opioid-induced)                  â”‚
â”‚                                                           â”‚
â”‚ ASSESSMENT PRIORITIES:                                     â”‚
â”‚ Medication history, recent procedures, associated symptoms, â”‚
â”‚ dehydration status, neurological examination               â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Card 2 â€“ Static Physical Exam/Medications & Selection

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ PHYSICAL EXAM & ANTIEMETIC MEDICATIONS                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ FOCUSED EXAMINATION:                                       â”‚
â”‚ â€¢ Vitals: Orthostatic changes, tachycardia, hypotension    â”‚
â”‚ â€¢ General: Dehydration signs, nutritional status           â”‚
â”‚ â€¢ Abdominal: Distension, bowel sounds, tenderness, masses  â”‚
â”‚ â€¢ Neurologic: Mental status, focal deficits, papilledema   â”‚
â”‚                                                           â”‚
â”‚ ğŸ’Š ANTIEMETIC MEDICATION CLASSES:                          â”‚
â”‚ 5-HT3 ANTAGONISTS (First-line):                           â”‚
â”‚ â€¢ Ondansetron: 4-8mg IV q8h, QTc monitoring needed        â”‚
â”‚ â€¢ Granisetron: 1mg IV daily, longer acting, less QTc risk  â”‚
â”‚                                                           â”‚
â”‚ DOPAMINE ANTAGONISTS:                                      â”‚
â”‚ â€¢ Metoclopramide: 10mg IV q6h, prokinetic effect, EPS risk â”‚
â”‚ â€¢ Prochlorperazine: 5-10mg IV q6h, good for migraine      â”‚
â”‚ â€¢ Haloperidol: 0.5-2mg IV q6h, very effective, QTc risk   â”‚
â”‚                                                           â”‚
â”‚ CORTICOSTEROIDS:                                           â”‚
â”‚ â€¢ Dexamethasone: 4-8mg IV daily, CINV prevention/delayed   â”‚
â”‚                                                           â”‚
â”‚ ANXIOLYTICS:                                               â”‚
â”‚ â€¢ Lorazepam: 0.5-1mg IV q6h, anticipatory nausea          â”‚
â”‚                                                           â”‚
â”‚ SPECIALIZED AGENTS:                                        â”‚
â”‚ â€¢ Scopolamine: 1.5mg patch q72h (motion sickness)         â”‚
â”‚ â€¢ Olanzapine: 10mg PO daily (refractory CINV)             â”‚
â”‚ â€¢ Aprepitant: 125mg PO day 1 (NK-1 antagonist, CINV)      â”‚
â”‚                                                           â”‚
â”‚ COMBINATION STRATEGIES:                                    â”‚
â”‚ â€¢ Use different receptor classes                           â”‚
â”‚ â€¢ Rotate agents q4-6h to avoid tachyphylaxis              â”‚
â”‚ â€¢ Scheduled dosing + PRN breakthrough                      â”‚
â”‚                                                           â”‚
â”‚ ğŸ’§ HYDRATION & SUPPORTIVE CARE:                           â”‚
â”‚ â€¢ IV fluids: NS/LR based on deficit, typically 125-250mL/hrâ”‚
â”‚ â€¢ Electrolyte monitoring: K+, Mg2+ (hypokalemia common)    â”‚
â”‚ â€¢ Thiamine supplementation if chronic alcohol/malnutrition â”‚
â”‚                                                           â”‚
â”‚ MONITORING PARAMETERS: QTc interval with multiple agents,  â”‚
â”‚ fluid balance, electrolytes, extrapyramidal symptoms       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## FLOWCHART (Bottom Panel â€“ Mermaid Algorithm)

```mermaid
graph TD
    A[Nausea/Vomiting Recognition]
    B[Assess Severity & Vitals plus Orthostatics]
    C{Dehydration Present?}
    D[IVF Resuscitation & Electrolyte Check]
    E[Proceed to Etiology Assessment]
    F{Likely Cause?}
    G[CINV Protocol & Multi-drug Regimen]
    H[Reduce Opioid Dose & Add Scheduled Antiemetic]
    I[CHS Protocol & Haloperidol plus Hot Showers]
    J[Broad Approach & R/O Obstruction]
    K{Response in 30min?}
    L[Continue Current & Add PRN]
    M[Add Different Class & Consider Admission]
    N[Bowel Regimen & Methylnaltrexone]
    O[Cessation Counseling & Admit for Control]
    P[Labs plus Imaging & Sequential Antiemetics]
    Q{Oral Intake Possible?}
    R[PO Regimen & Discharge Planning]
    S[Admit for IV Antiemetics]

    A --> B
    B --> C
    C -- Yes --> D
    C -- No --> E
    D --> E
    E --> F
    F -- Chemotherapy --> G
    F -- Opioid --> H
    F -- Cannabis --> I
    F -- Unknown --> J
    G --> K
    K -- Yes --> L
    K -- No --> M
    H --> N
    I --> O
    J --> P
    M --> Q
    Q -- Yes --> R
    Q -- No --> S
```

## INTERACTIVE ELEMENTS

### Antiemetic Rotation Scheduler
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚     ANTIEMETIC ROTATION SCHEDULE        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ FAILED AGENT: Ondansetron 8mg IV        â”‚
â”‚                                         â”‚
â”‚ OPTIMIZED ROTATION PLAN:                â”‚
â”‚                                         â”‚
â”‚ 14:30 - Metoclopramide 10mg IV âœ“ Given â”‚
â”‚ 18:30 - Promethazine 12.5mg IV         â”‚
â”‚ 22:30 - Haloperidol 1mg IV              â”‚
â”‚ 02:30 - Prochlorperazine 10mg IV       â”‚
â”‚ 06:30 - Return to ondansetron          â”‚
â”‚                                         â”‚
â”‚ BREAKTHROUGH OPTIONS:                   â”‚
â”‚ â€¢ Lorazepam 0.5mg IV q6h PRN           â”‚
â”‚ â€¢ Dexamethasone 4mg IV q12h             â”‚
â”‚                                         â”‚
â”‚ RULES:                                  â”‚
â”‚ â€¢ Avoid same class within 4 hours       â”‚
â”‚ â€¢ Monitor QTc with multiple agents      â”‚
â”‚ â€¢ Document effectiveness each dose      â”‚
â”‚                                         â”‚
â”‚ [UPDATE SCHEDULE] [EFFECTIVENESS LOG]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### QTc Risk Assessment Tool
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      QTc PROLONGATION RISK CALCULATOR   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ BASELINE ECG: QTc 442 ms (borderline)   â”‚
â”‚                                         â”‚
â”‚ CURRENT QTc-PROLONGING AGENTS:          â”‚
â”‚ â˜‘ Ondansetron (moderate risk)           â”‚
â”‚ â˜‘ Haloperidol planned (high risk)       â”‚
â”‚ â˜ Methadone                             â”‚
â”‚ â˜ Fluoroquinolones                      â”‚
â”‚                                         â”‚
â”‚ ADDITIONAL RISK FACTORS:                â”‚
â”‚ â˜ Hypokalemia (K+ 3.2)                 â”‚
â”‚ â˜ Hypomagnesemia                       â”‚
â”‚ â˜‘ Female gender                        â”‚
â”‚ â˜ Age >65                              â”‚
â”‚                                         â”‚
â”‚ RISK LEVEL: ğŸŸ¡ MODERATE-HIGH            â”‚
â”‚                                         â”‚
â”‚ RECOMMENDATIONS:                        â”‚
â”‚ â€¢ Check ECG before haloperidol          â”‚
â”‚ â€¢ Correct K+ to >4.0, Mg2+ >2.0        â”‚
â”‚ â€¢ Limit haloperidol to 1mg maximum     â”‚
â”‚ â€¢ Space QTc drugs by â‰¥4 hours          â”‚
â”‚ â€¢ Recheck ECG if QTc >480ms             â”‚
â”‚                                         â”‚
â”‚ [ORDER ECG] [ELECTROLYTE REPLETION]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Hydration Status Monitor
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚      VOLUME STATUS ASSESSMENT           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ORTHOSTATIC VITAL SIGNS:                â”‚
â”‚ Supine: BP 108/68, HR 96               â”‚
â”‚ Standing: BP 92/56, HR 120              â”‚
â”‚ Changes: â†“16 mmHg SBP, â†‘24 bpm HR      â”‚
â”‚                                         â”‚
â”‚ ORTHOSTATIC STATUS: ğŸ”´ POSITIVE         â”‚
â”‚ (>20 bpm HR increase OR >20 mmHg SBP drop)â”‚
â”‚                                         â”‚
â”‚ ESTIMATED FLUID DEFICIT: ~1.5-2L        â”‚
â”‚ Based on: Clinical dehydration signs    â”‚
â”‚                                         â”‚
â”‚ RESUSCITATION PLAN:                     â”‚
â”‚ â€¢ NS 500mL bolus over 30 minutes        â”‚
â”‚ â€¢ Then NS 125mL/hr continuous           â”‚
â”‚ â€¢ Goal UOP >0.5mL/kg/hr (>35mL/hr)     â”‚
â”‚                                         â”‚
â”‚ MONITORING:                             â”‚
â”‚ â€¢ Reassess orthostatics in 4 hours      â”‚
â”‚ â€¢ Daily weights on same scale           â”‚
â”‚ â€¢ Electrolyte panel in AM               â”‚
â”‚                                         â”‚
â”‚ RESPONSE INDICATORS:                    â”‚
â”‚ â˜ Orthostatics resolve                  â”‚
â”‚ â˜ Adequate urine output                 â”‚
â”‚ â˜ Improved oral tolerance               â”‚
â”‚                                         â”‚
â”‚ [REASSESS VITALS] [FLUID BALANCE]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

## VIRTUA VOORHEES ANTIEMETIC MANAGEMENT ADDENDA

- **Pharmacy Consultation:** Clinical pharmacist available for complex antiemetic regimens, drug interactions, and QTc monitoring protocols
- **Oncology Support:** 24/7 oncology team via Transfer Center 856-886-5111 for CINV management and breakthrough protocols
- **Gastroenterology Services:** Available for refractory nausea workup including gastroparesis evaluation and endoscopic assessment
- **Quality Metrics:** Time to effective symptom control, appropriate antiemetic selection, readmission rates for inadequate symptom management

## REFERENCE (GUIDELINE & SOURCE)
American Society of Clinical Oncology. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020.  
https://ascopubs.org/doi/10.1200/JCO.20.01296

**Additional References:**  
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. 2023.  
https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf

American Gastroenterological Association Clinical Practice Guidelines for the Management of Gastroparesis. 2022.  
https://www.gastrojournal.org/article/S0016-5085(22)00547-2/fulltext

Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020.  
https://ascopubs.org/doi/10.1200/JCO.20.01296

Simonetto DA, et al. Cannabinoid Hyperemesis: A Case Series and Review of Prior Reports. Mayo Clin Proc. 2012.  
https://www.mayoclinicproceedings.org/article/S0025-6196(12)00568-9/fulltext

**All steps follow current evidence-based guidelines for antiemetic management with integrated medication rotation protocols, QTc risk assessment, and specialized approaches for CINV and cannabinoid hyperemesis syndrome.**
